阿立哌唑治疗首发精神分裂症的随机对照研究

目的 探讨阿立哌唑治疗首发精神分裂症的疗效及安全性。方法 采用开放性对照研究，随机将符合CCMD-3精神分裂症患者58例分为两组，28例给予阿立哌唑治疗，10～30mg／d。30例给予利培酮治疗，2～4mg／d。观察6周后经PANSS，BPRS及TESS量表评价疗效及不良反应。结果 治疗结束时，阿立哌唑组和利培酮组病人临床疗效无明显着差异（P〉0．05）。但不良反应发生率有显著差异（P〈0．05），阿立哌唑在静坐不能、内分泌和体重增加方面优于利培酮。结论 阿立哌唑治疗首发精神分裂症与利培酮一样有较好的疗效及安全性，且较少的副作用。

A Randomized Control Study Aripiprazole in the Treatment of First-episode Schizophrenia

Objective To evaluate the efficacy and safety of aripiprazole in the treatment of first-episode schizophrenic patients. Methods 58 patients with schizophrenia were divided into two groups, which treated with aripiprazole or resperidone respectively for 6 weeks. The experimental group was given aripiprazole 10~30 mg/d, and the control group was given resperidone 2~4mg/d. PANSS, BPRSS and TESS were used to evaluate the efficacy and adverse effect respectively. Results The clinical efficacy in the two groups had no significant difference (P>0.05). And the incidence of adverse effect had significant difference (P<0.05). It shows that aripiprazole is superior to risperidone in akathisia, endocrine change and weight gain. Conclusion Aripiprazole is as effective and safe as risperidone in the treatment of first-episode schizophrenic patients and fewer side effect.